Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis - Takeaways - MDSpire

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis

  • By

  • Jiangzhuo Wu

  • Hanbing Li

  • Ling Wei

  • Xiao Yan

  • Jiang Fang

  • Lin Peng

  • Xiaobo Zhao

  • July 15, 2026

Share

  • 1

    The systematic review analyzed 10 RCTs involving 8,069 patients to evaluate the impact of angiogenesis inhibitors in neoadjuvant chemotherapy for breast cancer.

  • 2

    Results indicated that neoadjuvant chemotherapy with angiogenesis inhibitors significantly increased the pathological complete response rate compared to regimens without these inhibitors.

  • 3

    In triple-negative breast cancer, the pathological complete response rate improved significantly, while no significant improvement was observed in hormone receptor-positive patients.

  • 4

    Survival outcomes, including disease-free survival and overall survival, showed no significant differences between the two treatment regimens.

  • 5

    The study highlights the need for further research to identify biomarkers for predicting treatment efficacy in neoadjuvant chemotherapy with angiogenesis inhibitors.

Original Source(s)

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis

  • by Jiangzhuo Wu, Hanbing Li, Ling Wei, Xiao Yan, Jiang Fang, Lin Peng, Xiaobo Zhao

  • July 15, 2026

Related Content

Giant solid pseudopapillary neoplasm of the pancreas in an adolescent girl: a case report with narrative review

GLA is associated with ESCC progression and chemotherapy response via DNA damage repair–related pathways

Prognostic significance of extracapsular extension in patients with non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a retrospective cohort study